🇺🇸 FDA
Pipeline program

Livmoniplimab, Budigalimab

M19-345

Phase 1 small_molecule active

Quick answer

Livmoniplimab, Budigalimab for Locally Advanced or Metastatic Solid Tumors, Solid Tumors is a Phase 1 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).

Program details

Company
AbbVie Deutschland GmbH & Co. KG
Indication
Locally Advanced or Metastatic Solid Tumors, Solid Tumors
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials